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BACKGROUND: Patients with colorectal cancer (CRC) may suffer significant economic hardship during treatment. Complications are
common after surgery for CRC and may exacerbate the financial burden of CRC even further. METHODS: Within a population-based
survey of patients with stage III CRC, the authors investigated the effects of disease and treatment on personal finances and com-
puted a composite measure of financial burden. Correlations were examined between components of financial burden and patient-
reported postoperative complications using chi-square analyses, and Mantel-Haenszel chi-square tend tests were used to evaluate
correlations between composite financial burden scores and surgical complications, controlling for patient characteristics and other
factors by using multivariable Poisson regression. RESULTS: Among 937 respondents, 224 (24%) reported complications after sur-
gery. Those with complications had significantly higher composite financial burden (P<.001 for trend): they were more likely to spend
savings (40% vs 31%; P5.01), borrow or take loans (18% vs 11%; P5.007), fail to make credit card payments (18% vs 11%; P5.005),
reduce spending for food or clothes (38% vs 27%; P5.001), and decrease recreational activities (41% vs 33%; P5.03). They took sig-
nificantly longer to return to work (P5.009) and were more likely to experience significant worry about finances (61% vs 52%;
P5.01). CONCLUSIONS: Complications after surgery for CRC result in significant personal financial consequences as well as morbid-
ity. Financial stress impairs quality of life and may prevent adherence to recommended treatments. Therefore, patients who suffer
complications may require not just additional clinical care but also economic support and services. Cancer 2014;120:3074-81. VC 2014
American Cancer Society.
KEYWORDS: colorectal cancer, colectomy, complications, patients, quality of life, survivorship, employment, finances, socioeconomic
factors.
INTRODUCTION
Colorectal cancer (CRC) is the second leading cause of cancer-related death in the United States. Each year, approximately
140,000 Americans are diagnosed with CRC,1 and more than 250,000 colon resections are performed in the United
States.2 Surgery is the primary therapy for potentially curable colon cancer, but operative complications are common and
incur significant morbidity.3-5 Colectomy accounts for 10% of general surgery operations in the American College of Sur-
geons’ National Surgical Quality Improvement Program but for 25% of the complications, making it the most common
cause of postoperative death and prolonged hospitalization.4 These complications substantially increase the costs of surgi-
cal care for both hospitals and payors.6,7
Beyond the clinical consequences, however, many patients with cancer also suffer significant economic hardship
from their disease and its treatment.8-11 Even among those with medical insurance, cancer therapies may require substan-
tial out-of-pocket expenditures for medications, copayments for diagnostic testing, hospital and outpatient care, travel,
and home care.10-13 The financial impact of cancer can result in significant emotional and family stress and may impair
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overall quality of life.11,14 Yet the personal economic
effects of surgical adverse events, disability, and extended
hospitalization have not been established.
Recognizing that prevention of complications and
attention to patient-centered outcomes are priorities in
ongoing quality-improvement initiatives in both surgery
and oncology, we sought to understand the relation
between perioperative complications and patient-reported
personal financial burden associated with cancer treat-
ment. For this analysis, we used data from a detailed
population-based survey of patients with stage III CRC.
MATERIALS AND METHODS
Study Population
We identified all patients aged 21 years who underwent
surgical resection for pathologic stage III colon or rectal
cancer between August 2011 and March 2013 in the Sur-
veillance, Epidemiology, and End Results (SEER) cancer
registries of Metropolitan Detroit, Michigan and the State
of Georgia. Patients were eligible for recruitment within 3
to 12 months after undergoing surgical resection for
CRC. Exclusion criteria included stage IV disease, a
change in diagnosis based on final histology, death, or res-
idence outside of the catchment area. This analysis is
nested within a broader survey examining patient
decision-making around adjuvant therapy for CRC.
Data Collection
We identified physicians of record from pathology reports
and notified them of our intention to contact the study
patients. Allowing a brief response period for the physicians,
patients were then contacted by mail and invited to partici-
pate in the survey. A modified version of the Dillman
approach was used for recruitment, including sequential
follow-up steps in the event of nonresponse.15 Survey
responses were accepted up to 1 year from the date of sur-
gery. Upon receipt of surveys, extensive data checks for logic,
errors, and omissions were performed, and patients were
recontacted as necessary to obtain correct information.
The study protocol was approved by the institu-
tional review boards of the University of Michigan,
Wayne State University, Emory University, the State of
Michigan, and the State of Georgia Department of Public
Health. The research information sheet in the survey
packet included a statement of the study purpose, risks
and benefits of participation, and patient confidentiality.
Measures
The survey components pertinent to this analysis are
included in Supporting Figure 1 (see online supporting
information). The primary outcome in this study was per-
sonal financial burden, which was assessed through a series
of 7 binary questions asking patients about how CRC or
its treatment affected finances. Respondents were given a
checklist and asked to indicate which, if any, of the follow-
ing they had experienced: “I had to use savings,” “I had to
borrow money or take out a loan,” “I could not make pay-
ments on credit cards or other bills,” “I cut down on
spending for food and/or clothes,” “I cut down on spend-
ing for health care for other family members,” “I cut
down on recreational activities,” and “I cut down on
expenses in general.” We also asked patients how much
cumulative time they missed work as a consequence of
their cancer and its treatment. These measures were
derived from the national Consumer Bankruptcy Pro-
ject16,17 and have been used previously in studies of finan-
cial burden associated with the care of patients with
cancer.18
The primary exposure was the occurrence of 1 or
more postoperative complications. This measure was
determined by response to the query, “Did you have any
unexpected complications after your surgery?” Additional
covariates in the survey included SEER catchment area,
self-reported demographics (age at diagnosis, sex, race,
and marital status), socioeconomic status (based on meas-
ures defined by the National Health Interview Survey,
including measures of education and income), type of
health insurance, receipt of chemotherapy, overall
health status, and comorbid conditions. Respondents
with missing income data were grouped in a separate
category.
Next, we computed a composite measure of finan-
cial burden (score range, 0-7, with higher scores denoting
increased financial burden) by summing responses to
7 questions. The composite measure was internally
evaluated against a binary question on global financial
burden (“My illness has had no impact on my finances”)
and a single question about financial worry (“How much
do you worry about financial problems that have resulted
from your colorectal cancer and its treatment?” Worry
was evaluated on a 5-point Likert scale that we dichotom-
ized in accordance with our previous work (in which
scores of 1-3 were considered low, and scores of 4-5 were
considered high).19 The results from this assessment of in-
ternal consistency of the financial burden composite score
are presented below.
Statistical Analyses
We evaluated associations between financial burden, com-
plications, and other covariates using chi-square tests, and
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compared the composite financial burden score against
the summary financial burden and financial worry items
using the Mantel-Haenszel chi-square trend test. Because
the distribution of scores was weighted toward the lowest
counts, we then used multivariable Poisson regression to
control for covariates in the correlations between compos-
ite financial burden and complications and to compute
adjusted financial burden scores. All statistical tests were
2-sided, and P values< .05 were considered statistically
significant. All analyses were conducted using the SAS ver-
sion 9.3 software package (SAS Institute, Inc., Cary, NC).
RESULTS
Study Sample and Response Rate
A flowchart of enrollment and survey completion is pro-
vided as Supporting Figure 2 (see online supporting infor-
mation). Among 1563 eligible patients, 119 (8%) could
not be located, and 488 (31%) were located but did not
complete or return the survey. There were 956 completed
surveys available for evaluation (response rate, 66%). We
excluded from all analyses 19 of the 956 patients (2%)
TABLE 1. Respondent Characteristics and Reported
Complications
No. of Patients (%)
Characteristic
No Complications,
N5 713 (76)
Complications,
N5 224 (24) Pa
SEER Catchment Area .18
Georgia 480 (67) 140 (63)
Metropolitan Detroit 233 (33) 84 (38)
Age at diagnosis, y .47
<50 116 (16) 33 (15)
50-64 269 (38) 78 (35)
65-74 158 (22) 61 (27)
75 170 (24) 52 (23)
Sex .87
Men 377 (53) 118 (54)
Women 331 (47) 101 (46)
Race .16
White 502 (70) 168 (75)
Black 163 (23) 47 (21)
Other 48 (7) 8 (4)
Marital status .15
Not married/partnered 293 (41) 80 (36)
Married/partnered 420 (59) 144 (64)
Education .65
<High school 111 (16) 35 (16)
High school 179 (26) 48 (22)
Some college 230 (33) 74 (33)
College graduate 181 (26) 64 (29)
Annual Income .75
$90,000 102 (14) 40 (18)
$50,000-$89,999 160 (22) 45 (20)
$20,000-$49,999 193 (27) 59 (26)
<$20,000 119 (17) 42 (19)
Missing 139 (20) 40 (18)
Insurance .16
Private 306 (43) 88 (40)
Medicare 311 (44) 110 (50)
Medicaid 24 (3) 11 (5)
None 66 (9) 13 (6)
Chemotherapy .63
Yes 611 (86) 189 (84)
No 102 (14) 35 (16)
Overall health .43
Excellent 105 (15) 29 (13)
Very good 203 (29) 66 (30)
Good 250 (36) 84 (38)
Fair 104 (15) 24 (11)
Poor 42 (6) 18 (8)
Comorbidities < .001
None 199 (28) 33 (15)
1 219 (31) 73 (33)
2 295 (41) 118 (53)
Abbreviations: SEER, Surveillance, Epidemiology, and End Results.
aP values are derived from chi-square tests. Proportions may not add to
100% because of rounding or missing data.
Figure 1. These charts illustrate an internal consistency evalu-
ation of the composite financial burden score. (Top) This
chart illustrates the association of financial burden scores
with responses to the statement, “My illness has had no
impact on my finances.” Respondents who reported no
impact on their finances had significantly lower composite fi-
nancial burden scores (P< .001). (Bottom) This chart illus-
trates the association of financial burden scores with the
level of worry about finances. Respondents who reported
high levels of worry had significantly higher composite finan-
cial burden scores (P< .001).
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who did not answer the question about complications
(the primary exposure), leaving a final analytic sample of
937 respondents.
Respondent Characteristics and Complications
Postoperative complications were reported by 224 of the
937 patients (24%). Correlations between the incidence
of complications and the demographics, socioeconomic
factors, and health status of respondents are displayed in
Table 1. Patients with complications were significantly
more likely than those without complications to report 2
or more comorbid conditions (53% vs 41%; P< .001).
There was no statistically significant difference in the like-
lihood of complications according to SEER catchment
area age, sex, race, marital status, education, income, in-
surance, receipt of chemotherapy, or self-reported health.
Financial Burden,Worry, and Composite
Financial Burden Scores
Among all respondents, 356 (38%) did not endorse any
of the 7 measures of financial burden: 274 (29%)
endorsed 1 or 2, 208 (22%) endorsed 3 or 4, and 99
(11%) endorsed 5. Figure 1 provides comparisons of
composite financial burden scores against overall meas-
ures of financial burden and worry. Among 284 respond-
ents who reported that their illness had “no impact on
(their) finances,” 266 respondents (94%) had a composite
financial burden score of zero. Likewise, 272 of respond-
ents (66%) who reported low levels of worry about finan-
ces had composite financial burden scores of zero. Higher
financial burden scores were significantly more common
among those who reported that cancer did have an impact
on their finances (P< .001) and among those who
reported high levels of worry (P< .001).
Financial Burden and Postoperative
Complications
Table 2 displays the associations between patient-reported
aspects of financial burden and the occurrence of postop-
erative complications. Respondents who experienced
postoperative complications were significantly more likely
to report that their cancer and/or its treatment forced
them to use their savings (40% vs 31%; P5 .01), borrow
money or take out loans (18% vs 11%; P5 .007), fail to
pay credit cards or other bills (18% vs 11%; P5 .005),
reduce spending on food or clothes (38% vs 27%;
P5 .001), and reduce recreational activities (41% vs
33%; P5 .03). There were no significant associations
between surgical complications and reduced spending on
health care for other family members or on general
expenses.
Compared with respondents who had an uncompli-
cated postoperative course, those with complications were
significantly less likely to endorse none of the measures of
personal financial burden (30% vs 41%), and they were
significantly more likely to endorse 3 or 4 (26% vs 21%)
or 5 (15% vs 9%; P< .001 for trend) of the 7 measures
of financial burden (Fig. 2). In multivariable Poisson
regression (Table 3), SEER region, age, income, receipt of
Figure 2. Financial burden scores are illustrated according to
reported postoperative complications. Patients who reported
complications had significantly higher composite financial
burden scores (P<.001 for trend) and were less likely to
report none of the elements of financial burden.
TABLE 2. Association of Reported Complications With Financial Burden and Worry
Survey Item
No Complications,
N5 713 (76%)
Complications,
N5 224 (26%) Pa
“I had to use savings” 223 (31) 90 (40) .01
“I had to borrow money or take out a loan” 81 (11) 41 (18) .007
“I could not make payments on credit cards or other bills” 79 (11) 41 (18) .005
“I cut down on spending for food and/or clothes” 191 (27) 86 (38) .001
“I cut down on spending for health care for
other family members”
34 (5) 15 (7) .26
“I cut down on recreational activities” 237 (33) 92 (41) .03
“I cut down on expenses in general” 336 (47) 115 (51) .27
aP values are derived from chi-square tests.
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chemotherapy, and health status were all related inde-
pendently to composite financial burden. However, con-
trolling for these covariates and for sex, race, marital
status, education, and comorbidities did not significantly
attenuate the relation between financial burden scores and
complications (crude scores: 2.15 vs 1.66; P5 .03;
adjusted scores: 2.21 vs 1.69; P< .001).
Complications and Worry About Finances
Consistent with the greater frequency of reported finan-
cial burden, respondents who reported complications also
were significantly more likely to report high levels of
worry about their financial circumstances (61% vs 52%;
P5 .01).
Complications and Return to Work
Patients who experienced complications were significantly
more likely to have delayed return to work (P5 .009 for
trend), as illustrated in Figure 3. Whereas 50% of patients
without complications returned to work within 3 months,
just 37% of those who reported complications returned to
work in that interval. This differential persisted at 6
months (71% vs 59%) and 12 months after surgery (85%
vs 76%); and, ultimately, those with complications were
significantly more likely to stop working altogether (24%
vs 15%; P5 .04).
DISCUSSION
In this study of patient-reported clinical and economic
outcomes after surgery for stage III CRC, we observed sig-
nificantly greater personal financial burden among
patients who experienced postoperative complications.
Nearly 25% of respondents experienced complications af-
ter surgery—a rate consistent with most other series.20-23
Survey respondents who reported complications experi-
enced longer time off work and were more likely to never
resume working. They were more likely to cut back on
spending for food, clothes, and recreation and to accumu-
late debt or be unable to pay bills. They were also more
likely to experience high levels of worry about finances.
These patient-reported outcomes are consistent with
estimates from national databases suggesting that, beyond
the direct costs of cancer treatment, the average CRC
patient invests nearly $5000 worth of personal time par-
ticipating in their treatment plan.24 Patients incur large
out-of-pocket costs for their medications, physician visits,
and hospital care.10-13 Surgery, chemotherapy, and hospi-
talization cause work absences; lost wages and opportunity
costs; and lost productivity, training, education, and job
prospects for both patients and their family mem-
bers.10,11,25-27 Many cancer patients never return to work
at all, even after completing treatment.26,28-31 Indeed, the
personal financial costs of cancer are a common cause of
personal bankruptcy—patients with CRC are 3 times
more likely to experience bankruptcy than healthy, age-
matched individuals.8
Unfortunately, there is often little awareness of the
financial burdens that patients with CRCmay face during
treatment. Less than half of patients with stage III CRC
TABLE 3. Multivariable Poisson Regression Model
Predicting Level of Financial Burden Composite
Score According to Patient Characteristics and
Occurrence of Postoperative Complications
Parameter Effect Estimatea 95% CI P
Complications
No Reference
Yes 0.31 0.20, 0.42 < .001
SEER region
Metropolitan Detroit Reference
Georgia 0.28 0.17, 0.39 < .001
Age, y
<50 Reference
50-64 20.22 20.36, 0.10 < .001
65-74 20.68 20.83, 20.52 < .001
75 21.00 21.19, 20.80 < .001
Sex
Women Reference
Men 0.08 20.02, 0.18 .14
Race
White Reference
Black 0.001 20.11, 0.12 .09
Other 0.16 20.02, 0.36 .09
Marital status
Married/partnered Reference
Not married/partnered 20.09 20.20, 0.03 .13
Education
<High school Reference
High school 0.03 20.13, 0.19 .75
Some college 0.03 20.13, 0.18 .75
College graduate 20.07 20.25, 0.10 .41
Income
$90,000 Reference
$50,000-$89,000 0.32 0.15, 0.50 < .001
$20,000-$49,000 0.65 0.46, 0.83 < .001
<$20,000 0.41 0.19, 0.63 < .001
Missing 0.12 20.10, 0.34 .28
Chemotherapy
No Reference
Yes 0.54 0.32, 0.75 < .01
Health status
Excellent Reference
Very good 0.20 0.04, 0.37 .02
Good 0.23 0.06, 0.40 .007
Fair 0.30 0.10, 0.50 .003
Poor 0.18 20.06, 0.43 .15
Comorbidities
None Reference
1 20.10 20.24, 0.04 .16
2 20.04 20.18, 0.10 .58
Abbreviations: CI, confidence interval; SEER, Surveillance, Epidemiology,
and End Results.
a Positive effect estimates denote higher composite financial burden.
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discuss problems of treatment costs with their physi-
cians.9 Furthermore, previous studies have not evaluated
the role that treatment complications may play in
patients’ susceptibility to economic hardship. Therefore,
surgeons and other providers need to be particularly
aware that patients with CRC who suffer treatment-
related complications are at increased risk for economic
hardship during treatment.
The financial burden of surgical complications also
may have broader implications for CRC outcomes. First,
there is a strong association between financial and emo-
tional strain and overall quality of life.32 Patients who
experience economic hardship during cancer treatment
are significantly more likely to report emotional dis-
tress,11,14,33 which has the potential to exacerbate their
care needs, delay return to work, and, in turn, make the
financial challenges even greater.11,12 Second, personal
finances are recognized as an important factor in patients’
ability to receive optimal therapy for cancer.34 Anywhere
from 9% to 20% of cancer patients report missing essen-
tial medical care because of personal cost,12,35,36 and the
likelihood of economically-motivated nonadherence is
even greater among cancer patients who are younger,35
have the lowest incomes,12 or are uninsured.36 Further-
more, disease-related job loss and disability substantially
increase nonadherence with recommended cancer ther-
apy.9 Therefore, if the personal economic consequences of
adverse clinical outcomes from CRC surgery contribute to
patients’ failure to complete necessary therapy, then there
may be an important decrement in long-term oncologic
outcomes related to job loss and disability attributable to
CRC surgery. In addition, patients who experience com-
plications after surgery may require access to additional fi-
nancial and logistical support to complete needed cancer
therapies.
In this study, we relied on patient-reported clinical
outcomes, which may limit precision regarding the defini-
tions and types of surgical complications. However,
patient-reported complications are generally highly
valid37 and strongly correlated with surgeon reports.38
With increasing interest in patient-reported outcomes in
surgery and cancer care,39 the value of insight into
patients’ perceptions and experiences from our survey out-
weighs loss of clinical detail. We also rely on respondents’
reporting of their financial burden, which is inherently
subjective, and we cannot specifically assess the causal
relations between complications, cancer treatment, and
the objective financial effects—patients with cancer could
cut back on discretionary spending because of financial
burden or just because their disease and treatment limit
their activities. In addition, this study was limited to
patients with stage III CRC, because it was nested within
a broader survey of patient decision-making around adju-
vant therapy. Nevertheless, there is little reason to believe
that the population-based findings herein would not gen-
eralize to other patients who undergo surgery for CRC
and other solid tumors.
In summary, we observed that, for patients who
undergo surgery for stage III CRC, postoperative compli-
cations are common and significantly affect patients’
Figure 3. The amount of work missed because of colorectal cancer and/or its treatment is illustrated according to the reported
incidence of complications. Patients who had complications were significantly more likely to be out of work for a longer duration
(P5.009 for trend) and were more likely never to return (P5.04).
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personal financial burden and distress. Above and beyond
the clinical consequences, therefore, the prevention and
mitigation of surgical complications will be key measures
to support patients’ psychological well being, quality of
life, recovery, and compliance with recommended ther-
apy. To our knowledge, this correlation between the clini-
cal and the personal economic outcomes of cancer surgery
has not been previously recognized. Therefore, future pol-
icy advocacy should aim to encourage the widespread pro-
vision of job-related benefits that would compensate
patients for lost work and ensure employability after re-
covery. Alternatively, patients who require surgery and/or
chemotherapy for cancer might be made eligible for finan-
cial assistance, scaled in proportion to the extent of their
treatments and the morbidities experienced. With increas-
ing longevity and survival from cancer, these will be im-
portant contributors to the financial and clinical
outcomes and quality of life for cancer survivors.
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